Nalfurafine: Difference between revisions

	WikiDoc Resources for Nalfurafine
Articles
Most recent articles on Nalfurafine Most cited articles on Nalfurafine Review articles on Nalfurafine Articles on Nalfurafine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nalfurafine Images of Nalfurafine Photos of Nalfurafine Podcasts & MP3s on Nalfurafine Videos on Nalfurafine
Evidence Based Medicine
Cochrane Collaboration on Nalfurafine Bandolier on Nalfurafine TRIP on Nalfurafine
Clinical Trials
Ongoing Trials on Nalfurafine at Clinical Trials.gov Trial results on Nalfurafine Clinical Trials on Nalfurafine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nalfurafine NICE Guidance on Nalfurafine NHS PRODIGY Guidance FDA on Nalfurafine CDC on Nalfurafine
Books
Books on Nalfurafine
News
Nalfurafine in the news Be alerted to news on Nalfurafine News trends on Nalfurafine
Commentary
Blogs on Nalfurafine
Definitions
Definitions of Nalfurafine
Patient Resources / Community
Patient resources on Nalfurafine Discussion groups on Nalfurafine Patient Handouts on Nalfurafine Directions to Hospitals Treating Nalfurafine Risk calculators and risk factors for Nalfurafine
Healthcare Provider Resources
Symptoms of Nalfurafine Causes & Risk Factors for Nalfurafine Diagnostic studies for Nalfurafine Treatment of Nalfurafine
Continuing Medical Education (CME)
CME Programs on Nalfurafine
International
Nalfurafine en Espanol Nalfurafine en Francais
Business
Nalfurafine in the Marketplace Patents on Nalfurafine
Experimental / Informatics
List of terms related to Nalfurafine

Nalfurafine
Clinical data
Synonyms	TRK-820
AHFS/Drugs.com	International Drug Names
Routes of; administration	intravenous
ATC code	V03AX02 (WHO) ;
Identifiers
	IUPAC name (2E)-N-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide;
CAS Number	152658-17-8 ;
PubChem CID	6445230;
IUPHAR/BPS	1651;
ChemSpider	4949003 ;
UNII	XC41AVD567;
ChEMBL	ChEMBL267495 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C28H32N2O5
Molar mass	476.564 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7;
	InChI InChI=1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1 ; Key:XGZZHZMWIXFATA-UEZBDDGYSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 17:01, 13 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nalfurafine (INN and USAN;^[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.^[2]

As of January 2010^[update], it is also being investigated for the treatment of pruritus in patients with chronic liver disease.^[3]

References

↑ Statement on a Nonproprietary Name adopted by the USAN Council
↑ "AC-820". Acologix. 2009.
↑ Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov

[1] Statement on a Nonproprietary Name adopted by the USAN Council

[2] "AC-820". Acologix. 2009.

[3] Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
 {{Drugbox
-| IUPAC_name        = (''E'')-''N''-[17-(cyclopropylmethyl)-4,5α-epoxy-<br>3,14-dihydroxymorphinan-6β-yl]-3-(furan-3-yl)-<br>''N''-methylprop-2-enamide
+| Verifiedfields = changed
-| image             = Nalfurafine.svg
+| Watchedfields = changed
-| CAS_number        = 152658-17-8
+| verifiedrevid = 447928192
-| CAS_supplemental  =
+| IUPAC_name = (2''E'')-''N''-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- ''N''-methylacrylamide
-| ATC_prefix        =
+| image = Nalfurafine.png
-| ATC_suffix        =
-| ATC_supplemental  =
+<!--Clinical data-->
-| PubChem           = 6445230
+| tradename =
-| DrugBank          =
+| Drugs.com = {{drugs.com|international|nalfurafine}}
-| C=28 | H=32 | N=2 | O=5
+| licence_EU = <!-- EMEA requires brand name -->
-| molecular_weight  = 476.564 g/mol
+| licence_US = <!-- FDA may use generic name -->
-| smiles            =
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
-| synonyms          = TRK-820
+| pregnancy_US = <!-- A / B            / C / D / X -->
-| bioavailability   =
+| pregnancy_category =
-| protein_bound     =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| metabolism        =
+| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| elimination_half-life =
+| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| excretion         =
+| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| licence_EU        =  <!-- EMEA requires brand name -->
+| legal_status =
-| licence_US        =  <!-- FDA may use generic name -->
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
-| pregnancy_category=
-| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| legal_status      =
 | dependency_liability =
 | routes_of_administration = [[Intravenous therapy|intravenous]]
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 152658-17-8
+| ATC_prefix = V03
+| ATC_suffix = AX02
+| ATC_supplemental =
+| PubChem = 6445230
+| IUPHAR_ligand = 1651
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 267495
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = XC41AVD567
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
+| ChemSpiderID      = 4949003
+<!--Chemical data-->
+| C=28 | H=32 | N=2 | O=5
+| molecular_weight = 476.564 g/mol
+| synonyms = TRK-820
+| smiles = CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7
+| InChI             = 1/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1
+| InChIKey          = XGZZHZMWIXFATA-UEZBDDGYBW
+| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChI          = 1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1
+| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChIKey       = XGZZHZMWIXFATA-UEZBDDGYSA-N
 }}
+              __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]];<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf Statement on a Nonproprietary Name adopted by the USAN Council]</ref> also known as AC-820, TRK-820; trade name '''Remitch''') is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] marketed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].<ref>{{cite web|url=http://www.acologix.com/pipeline_ac-820.html|title=AC-820|publisher=Acologix|year=2009}}</ref>
+{{as of|2010|1}}, it is also being investigated for the treatment of pruritus in patients with [[chronic liver disease]].<ref>{{ClinicalTrialsGov|NCT00638495|Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease}}</ref>
-'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]]; also known as AC-820, TRK-820) is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] being developed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].
+==References==
+{{Reflist|2}}
-==External links==
-*http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf
-*http://www.acologix.com/pipeline_ac-820.html
-{{pharma-stub}}
-[[Category:Opioids]]
+[[Category:Morphinans]]
-[[Category:Drugs]]
+[[Category:Phenols]]
-{{WikiDoc Sources}}
+[[Category:Alcohols]]
+[[Category:Amides]]
+[[Category:Semisynthetic opioids]]
+[[Category:Alkenes]]
+[[Category:Furans]]
+[[Category:Drug]]

Nalfurafine: Difference between revisions

Latest revision as of 17:01, 13 April 2015

Overview

References

Navigation menu